The study provides insight into the disease state.
FDA Alerts
FDA Alerts
Thursday, January 19, 2017
The FDA recently has approved the topical treatment, oxymetazoline hydrochloride (Rhofade, Allergan plc) cream, for patients with persistent facial erythema associated with rosacea in adults.
FDA Alerts
Tuesday, August 25, 2015
FDA Alerts
Monday, May 12, 2014
Mirvaso is the first and only FDA-approved topical treatment for persistent erythema of rosacea.
The FDA approved Mirvaso (brimonidine) Topical Gel, 0.33% in August 2013 as the first and only topical treatment indicated for the persistent (non-transient) facial erythema of rosacea in adults age 18 or older. The gel, marketed by Galderma Laboratories, L.P., is an alpha-2 adrenergic agonist that may work by constricting the dilated blood vessels to reduce the redness of rosacea.
News
News
Monday, March 5, 2018
In a recent study, researchers investigated the safety and efficacy of a topical cream compared with vehicle for reducing erythema among patients with rosacea.
News
Tuesday, December 5, 2017
In a recent study, researchers examined the risk of rosacea in women with obesity.
News
Wednesday, October 25, 2017
The National Rosacea Society has awarded funding for 3 new studies, in addition to continuing support for 3 ongoing studies.
News
Wednesday, August 23, 2017
Recent research, funded by the National Rosacea Society, examined treatment options for patients with rosacea inflammation.
Research in Review
Research in Review
Tuesday, March 20, 2018
The study provides insight into the disease state.
Research in Review
Wednesday, December 27, 2017
Experts explain how the new classification system impacts clinical decision-making.
Research in Review
Thursday, November 23, 2017
A review of recent news, research, and treatment related to rosacea.
Research in Review
Thursday, November 9, 2017
A new standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwide, was recently published.